BAUSCH + LOMB CORP

NYSE: BLCO (Bausch + Lomb Corporation)

Kemas kini terakhir: 17 jam lalu

16.03

-0.15 (-0.93%)

Penutupan Terdahulu 16.18
Buka 16.16
Jumlah Dagangan 726,329
Purata Dagangan (3B) 460,658
Modal Pasaran 5,715,277,824
Harga / Pendapatan (P/E Ke hadapan) 15.02
Harga / Jualan (P/S) 1.11
Harga / Buku (P/B) 0.910
Julat 52 Minggu
10.99 (-31%) — 18.92 (17%)
Tarikh Pendapatan 29 Jul 2026
Margin Keuntungan -7.50%
Margin Operasi (TTM) -5.36%
EPS Cair (TTM) -1.02
Pertumbuhan Hasil Suku Tahunan (YOY) 3.50%
Jumlah Hutang/Ekuiti (D/E MRQ) 75.07%
Nisbah Semasa (MRQ) 1.56
Aliran Tunai Operasi (OCF TTM) 166.00 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 69.00 M
Pulangan Atas Aset (ROA TTM) 0.61%
Pulangan Atas Ekuiti (ROE TTM) -5.36%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Medical Instruments & Supplies (US) Bercampur Bercampur
Medical Instruments & Supplies (Global) Bercampur Menurun
Stok Bausch + Lomb Corporation Menaik Menaik

AISkor Stockmoo

0.0
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam 1.5
Volatiliti Harga -1.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal -2.0
Purata 0.00

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
BLCO 6 B - - 0.910
BDX 41 B 2.20% 26.12 1.62
WST 22 B 0.37% 41.51 7.70
ALC 30 B 0.35% 37.14 1.38
RMD 30 B 0.92% 19.97 4.62
STVN 4 B 0.21% 22.92 2.79

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Sektor Healthcare
Industri Medical Instruments & Supplies
Gaya Pelaburan Mid Core
% Dimiliki oleh Orang Dalam 88.13%
% Dimiliki oleh Institusi 10.97%

Pemilikan

Nama Tarikh Syer Dipegang
Caspian Capital Lp 31 Dec 2025 1,999,043
Julat 52 Minggu
10.99 (-31%) — 18.92 (17%)
Julat Harga Sasaran
16.00 (-0%) — 21.00 (31%)
Tinggi 21.00 (Citigroup, 31.00%) Beli
Median 20.00 (24.77%)
Rendah 16.00 (Stifel, -0.19%) Pegang
Purata 19.00 (18.53%)
Jumlah 2 Beli, 3 Pegang
Harga Purata @ Panggilan 17.72
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
HC Wainwright & Co. 23 Feb 2026 20.00 (24.77%) Beli 17.99
Barclays 19 Feb 2026 20.00 (24.77%) Pegang 17.65
Citigroup 19 Feb 2026 21.00 (31.00%) Beli 17.65
Stifel 19 Feb 2026 16.00 (-0.19%) Pegang 17.65
17 Feb 2026 15.00 (-6.43%) Pegang 17.73
Wells Fargo 19 Feb 2026 18.00 (12.29%) Pegang 17.65
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
ALFONSO EDUARDO 15.90 - 1,375 21,863
COLLIS STEVEN H 15.90 - 1,415 22,499
PAULSON JOHN 15.90 - 1,375 21,863
ROBERTSON RUSSEL C 15.90 - 1,611 25,615
Jumlah Keseluruhan Kuantiti Bersih 5,776
Jumlah Keseluruhan Nilai Bersih ($) 91,838
Purata Pembelian Keseluruhan ($) 15.90
Purata Jualan Keseluruhan ($) -
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
ALFONSO EDUARDO Pengarah 30 Apr 2026 Diperolehi (+) 1,375 15.90 21,863
COLLIS STEVEN H Pengarah 30 Apr 2026 Diperolehi (+) 1,415 15.90 22,499
PAULSON JOHN Pengarah 30 Apr 2026 Diperolehi (+) 1,375 15.90 21,863
ROBERTSON RUSSEL C Pengarah 30 Apr 2026 Diperolehi (+) 1,611 15.90 25,615

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda